Todays Report: The Jefferies Group Comments on Immunomedics Inc.’s Q1 2017 Earnings (IMMU)

The Jefferies Group Comments on Immunomedics Inc.’s Q1 2017 Earnings (IMMU)

Immunomedics Inc. (NASDAQ:IMMU) – Equities research analysts at Jefferies Group issued their Q1 2017 earnings per share estimates for Immunomedics in a research report issued on Thursday. Jefferies Group analyst M. Andrews anticipates that the firm will earn ($0.12) per share for the quarter. Jefferies Group currently has a “Buy” rating on the stock.

Several other equities research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Immunomedics from a “hold” rating to a “strong sell” rating in a research note on Monday, August 22nd. Wells Fargo & Co. lowered shares of Immunomedics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 21st.

Shares of Immunomedics (NASDAQ:IMMU) traded down 1.15% during midday trading on Friday, reaching $2.58. The company’s stock had a trading volume of 1,973,534 shares. The company’s market capitalization is $247.33 million. The stock has a 50 day moving average of $2.99 and a 200-day moving average of $3.03. Immunomedics has a 1-year low of $1.61 and a 1-year high of $5.44.

10/07/jefferies-group-comments-on-immunomedics-inc-s-q1-2017-earnings-immu.html

Immunomedics (NASDAQ:IMMU) last announced its quarterly earnings data on Wednesday, August 17th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by $0.06.

In other Immunomedics news, Director Don C. Stark sold 9,900 shares of the company’s stock in a transaction dated Wednesday, August 24th. The shares were sold at an average price of $2.97, for a total value of $29,403.00. Following the completion of the transaction, the director now owns 55,848 shares in the company, valued at approximately $165,868.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Mary E. Paetzold sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 23rd. The stock was sold at an average price of $2.98, for a total transaction of $44,700.00. Following the completion of the transaction, the director now owns 82,474 shares of the company’s stock, valued at approximately $245,772.52. The disclosure for this sale can be found here. 8.80% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of IMMU. BlackRock Group LTD boosted its position in Immunomedics by 108.6% in the second quarter. BlackRock Group LTD now owns 46,962 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 24,444 shares during the period. Creative Planning boosted its position in Immunomedics by 0.9% in the second quarter. Creative Planning now owns 58,485 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 510 shares during the period. Cubist Systematic Strategies LLC purchased a new position in Immunomedics during the second quarter valued at approximately $161,000. Chicago Equity Partners LLC purchased a new position in Immunomedics during the second quarter valued at approximately $258,000. Finally, Rhumbline Advisers boosted its position in Immunomedics by 13.0% in the second quarter. Rhumbline Advisers now owns 115,948 shares of the biopharmaceutical company’s stock valued at $269,000 after buying an additional 13,313 shares during the period. Hedge funds and other institutional investors own 53.79% of the company’s stock.

Immunomedics Company Profile

Related posts

Leave a Comment